Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Lymphocytic Leukemia Loss of Chromosome 17p | Drug: Ibrutinib Drug: Venetoclax | Phase 2 |
PRIMARY OBJECTIVES:
I. Overall response rate to combination ibrutinib and venetoclax after 12 cycles (intervention cohort).
II. Rate of mutation negative status after 12 cycles of combination venetoclax and ibrutinib (intervention cohort ).
SECONDARY OBJECTIVES:
I. Incidence of BTK C481S mutations during ibrutinib treatment (observation cohort).
II. Progression-free survival after development of a BTK C481S mutation (observation cohort).
III. Progression-free and overall survival after adding venetoclax to ibrutinib (intervention cohort).
IV. Type and incidence of adverse events during combination ibrutinib and venetoclax treatment in this patient population (intervention cohort).
EXPLORATORY OBJECTIVES:
I. Determine patient and disease characteristics associated with clinical disease progression in a univariable and multivariable analysis (observation cohort).
II. Determine the changes in the allelic frequency of ibrutinib resistance mutations after their development (observation cohort) and after venetoclax is added (intervention cohort).
III. Determine novel resistance mechanisms to ibrutinib and ibrutinib/venetoclax combination therapy by whole exome and ribonucleic acid (RNA) sequencing at baseline and clinical relapse.
IV. Perform BH3 profiling and correlate with response to combination venetoclax and ibrutinib therapy.
OUTLINE: This is a dose-escalation study of venetoclax.
OBSERVATION COHORT: Patients who are taking ibrutinib enter Observation cohort and undergo screening every 3 months for development for genetic mutations. If mutations develop, patients undergo increased screening for development of clinical disease progression. Patients who develop clinical disease progression with or without mutations enter the Intervention cohort.
INTERVENTION COHORT: Patients receive venetoclax orally (PO) daily and ibrutinib PO once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve minimal residual disease (MRD) negative complete remission (CR) after 12 or 24 cycles continue receiving ibrutinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months thereafter.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 160 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter Study of Ibrutinib Resistance Development and Intervention With Venetoclax (Phase II) |
Actual Study Start Date : | March 11, 2020 |
Estimated Primary Completion Date : | December 31, 2021 |
Estimated Study Completion Date : | December 31, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment (venetoclax, ibrutinib)
OBSERVATION COHORT: Patients who are taking ibrutinib enter observation cohort and undergo screening every 3 months for development for genetic mutations. If mutations develop, patients undergo increased screening for development of clinical disease progression. Patients who develop clinical disease progression with or without mutations enter the Intervention cohort. INTERVENTION COHORT: Patients receive venetoclax PO daily and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve MRD negative CR after 12 or 24 cycles continue receiving ibrutinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. |
Drug: Ibrutinib
Given PO
Other Names:
Drug: Venetoclax Given PO
Other Names:
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
History of active malignancies other than CLL within the past 3 years prior to study entry, with the exception of:
Contact: The Ohio State University Comprehensive Cancer Center | 1-800-293-5066 | OSUCCCClinicaltrials@osumc.edu |
United States, Michigan | |
Karmanos Cancer Institute | Recruiting |
Detroit, Michigan, United States, 48201 | |
Contact: Emily Tolksdorf, BS 313-576-9814 tolkdoe@karmanos.org | |
Principal Investigator: Erlene Seymour, MD | |
United States, Ohio | |
Ohio State University Comprehensive Cancer Center | Recruiting |
Columbus, Ohio, United States, 43210 | |
Contact: Kerry A. Rogers, MD 614-366-9338 kerry.rogers@osumc.edu | |
Principal Investigator: Kerry A. Rogers, MD | |
United States, Utah | |
Huntsman Cancer Institute | Not yet recruiting |
Salt Lake City, Utah, United States, 84112 | |
Contact: Kolleen Hicks 801-587-7604 Kolleen.Hicks@hci.utah.edu | |
Principal Investigator: Deborah Stephens, MD |
Principal Investigator: | Kerry A Rogers, MD | Ohio State University Comprehensive Cancer Center |
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date ICMJE | May 7, 2019 | ||||
First Posted Date ICMJE | May 9, 2019 | ||||
Last Update Posted Date | June 18, 2020 | ||||
Actual Study Start Date ICMJE | March 11, 2020 | ||||
Estimated Primary Completion Date | December 31, 2021 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
|
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Pre-specified Outcome Measures |
|
||||
Original Other Pre-specified Outcome Measures | Same as current | ||||
Descriptive Information | |||||
Brief Title ICMJE | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance | ||||
Official Title ICMJE | A Multicenter Study of Ibrutinib Resistance Development and Intervention With Venetoclax (Phase II) | ||||
Brief Summary | This phase II trial studies how well the combination of ibrutinib and venetoclax works in treating patients with chronic lymphocytic leukemia whose cancer has stopped responding to ibrutinib alone. Both ibrutinib and venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ibrutinib and venetoclax together after development of ibrutinib resistance may work better than discontinuing ibrutinib and switching to other chemotherapy drugs. | ||||
Detailed Description |
PRIMARY OBJECTIVES: I. Overall response rate to combination ibrutinib and venetoclax after 12 cycles (intervention cohort). II. Rate of mutation negative status after 12 cycles of combination venetoclax and ibrutinib (intervention cohort ). SECONDARY OBJECTIVES: I. Incidence of BTK C481S mutations during ibrutinib treatment (observation cohort). II. Progression-free survival after development of a BTK C481S mutation (observation cohort). III. Progression-free and overall survival after adding venetoclax to ibrutinib (intervention cohort). IV. Type and incidence of adverse events during combination ibrutinib and venetoclax treatment in this patient population (intervention cohort). EXPLORATORY OBJECTIVES: I. Determine patient and disease characteristics associated with clinical disease progression in a univariable and multivariable analysis (observation cohort). II. Determine the changes in the allelic frequency of ibrutinib resistance mutations after their development (observation cohort) and after venetoclax is added (intervention cohort). III. Determine novel resistance mechanisms to ibrutinib and ibrutinib/venetoclax combination therapy by whole exome and ribonucleic acid (RNA) sequencing at baseline and clinical relapse. IV. Perform BH3 profiling and correlate with response to combination venetoclax and ibrutinib therapy. OUTLINE: This is a dose-escalation study of venetoclax. OBSERVATION COHORT: Patients who are taking ibrutinib enter Observation cohort and undergo screening every 3 months for development for genetic mutations. If mutations develop, patients undergo increased screening for development of clinical disease progression. Patients who develop clinical disease progression with or without mutations enter the Intervention cohort. INTERVENTION COHORT: Patients receive venetoclax orally (PO) daily and ibrutinib PO once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve minimal residual disease (MRD) negative complete remission (CR) after 12 or 24 cycles continue receiving ibrutinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months thereafter. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 2 | ||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arms ICMJE | Experimental: Treatment (venetoclax, ibrutinib)
OBSERVATION COHORT: Patients who are taking ibrutinib enter observation cohort and undergo screening every 3 months for development for genetic mutations. If mutations develop, patients undergo increased screening for development of clinical disease progression. Patients who develop clinical disease progression with or without mutations enter the Intervention cohort. INTERVENTION COHORT: Patients receive venetoclax PO daily and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve MRD negative CR after 12 or 24 cycles continue receiving ibrutinib PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Interventions:
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE |
160 | ||||
Original Estimated Enrollment ICMJE |
36 | ||||
Estimated Study Completion Date ICMJE | December 31, 2021 | ||||
Estimated Primary Completion Date | December 31, 2021 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender ICMJE |
|
||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE |
|
||||
Listed Location Countries ICMJE | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT03943342 | ||||
Other Study ID Numbers ICMJE | OSU-18311 NCI-2019-02511 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) P30CA016058 ( U.S. NIH Grant/Contract ) |
||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product |
|
||||
IPD Sharing Statement ICMJE |
|
||||
Responsible Party | Kerry Rogers, Ohio State University Comprehensive Cancer Center | ||||
Study Sponsor ICMJE | Kerry Rogers | ||||
Collaborators ICMJE |
|
||||
Investigators ICMJE |
|
||||
PRS Account | Ohio State University Comprehensive Cancer Center | ||||
Verification Date | June 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |